title: Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin.
abstract: There has been a resurgence of interest in the use of colistin for the treatment of multidrug-resistant Gram-negative bacterial infections. A more favorable infection outcome is observed when colistin is used in combination with carbapenems. We present a patient with severe New Delhi metallo-β-lactamase-1 Escherichia coli infection who developed convulsions rapidly followed by acute respiratory muscle weakness and apnoea during treatment with colistin and meropenem. Chromatographic assay showed a "trough" colistin level that was approximately fourfold higher than previously reported maximum steady-state colistin plasma levels in critically ill patients. The patient's renal clearance never necessitated dose adjustments, suggesting that the observed high plasma colistin level might be due to impaired non renal elimination. Although meropenem itself has very low neurotoxic potential, its concomitant use with colistin may have elicited colistin neurotoxicity.
authors.affiliation: Department of Intensive Care, University Hospital, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium. herbert.spapen@uzbrussel.be
authors.forename: Herbert D
authors.initials: HD
authors.lastname: Spapen
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Honore
authors.forename: Nicolas
authors.initials: N
authors.lastname: Gregoire
authors.forename: Patrice
authors.initials: P
authors.lastname: Gobin
authors.forename: Jouke
authors.initials: J
authors.lastname: de Regt
authors.forename: Geert A
authors.initials: GA
authors.lastname: Martens
authors.forename: Denis
authors.initials: D
authors.lastname: Pierard
authors.forename: William
authors.initials: W
authors.lastname: Couet
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001049:Apnea / Q000139:chemically induced*; D002845:Chromatography; D003091:Colistin / Q000008:administration & dosage / Q000009:adverse effects*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry; D012640:Seizures / Q000139:chemically induced*; D013845:Thienamycins / Q000008:administration & dosage / Q000009:adverse effects; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D001618:beta-Lactamases; D000077731:Meropenem; D003091:Colistin